Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Epizyme, Inc. Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Ipsen to acquire Epizyme, expanding its portfolio in oncology June 27, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM IPSEY OTC Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting June 02, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme To Participate in H.C. Wainwright Global Investment Conference May 17, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update May 10, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Date of First Quarter 2022 Financial Results May 03, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 06, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update March 15, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results February 22, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Pricing of Public Offering of Common Stock January 27, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Proposed Public Offering of Common Stock January 26, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates January 10, 2022 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting December 12, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting December 11, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting December 02, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Updates to Its Board of Directors November 18, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme to Participate in Jefferies London Healthcare Conference November 12, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update November 09, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 05, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 November 04, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Date of Third Quarter 2021 Financial Results November 02, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making November 01, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 07, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress September 14, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 20, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Announces CEO Succession August 09, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update August 09, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China August 08, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM HCM Epizyme Announces Date of Second Quarter 2021 Financial Results August 03, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients June 16, 2021 From Epizyme, Inc. Via Business Wire Tickers EPZM Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.